Trust me, I'm hoping and have been betting that you are right.

If Buci is 16x stronger than NAC, it more than reasonable to believe that it'll be more effective in a Covid situation. Still waiting patiently riding free shares and don't plan on selling until 1)there's great news and approval and when it hits $10 eventually or 2) bad news and it hits .10

I'll give it until EOY for study/approval news. If no news by then, it'll look pretty bleak.

https://www.nacincovid.info/
https://www.nacincovid.info/why-nac/why-nac

Huh? Volume: 6,568 is not something to get excited about for anyone looking to buy this stock. Would never be able to sell with this daily/monthly lack of volume.

I found their website and for a company claiming to have 900 customers, it's outdated, incomplete and not exactly inspiring. The alleged float looks good but again, the scare is the lack of volume. Only ~ 60,000 shares traded in 3 months is a tough pill to swallow.

This may in fact be a decent company but with so little information out there, and no sizzle or steak, it's going to be hard to entice any real buying.

But I wish you success and hope for holders I'm proven wrong.

How can that be? Their 10Q's answer that question. I can't even find a website that works. If you have it, please share.

The Orphan Drug Designation program provides orphan status to drugs and biologics which are defined as those intended for the treatment, prevention or diagnosis of a rare disease or condition, which is one that affects less than 200,000 persons in the US or meets cost recovery provisions of the act.

Orphan drug status (designated by the FDA) gives a company exclusive marketing rights for a seven-year period, along with other benefits to recoup the costs of researching and developing drugs to treat rare diseases. The Orphan Drug Act was designed to encourage companies to develop drugs for rare diseases.

Also may enjoy the waiver of the $2.4 million new drug filing fee according to the PR.

In short, not approved for use. Yet.

Thanks for the continued diligence Renee...how you don't have 5,000 followers on this board is beyond me.

I've been in this (and yes, trading this) a looong time...since the low teens. I bought as a Covid play, but also because I've seen first hand what psych's can do with mental health. I have nothing to do with Walsh or his buys, small as they are.

I don't post much anymore (I've had my fill of battles, bashers and pumpers) and I'm going to ride this all the way up or down with pretty much house shares and the friggin' killing I made over the past year on CY**.

The story is good. If they can get this to market with positive results, it's dollars.

The Delta variant is child's play compared to the Lambda variant if that ever takes a strong hold throughout the world. Already in South America and showing resistance to vaccines. This one is bad. Very bad.

https://jcm.asm.org/content/58/8/e01233-20

In this study, the performance characteristics of OG were evaluated and showed a specificity of 100% and a sensitivity of 95.8% for samples collected ≥10?days after the onset of symptoms or a positive PCR result. This rapid test performance was equivalent to that of the Abbott SARS-CoV-2 IgG assay.

I'm assuming this is AYTU's manufacturer...

This stock is a gift and always has been!

Nothing wrong with your advice fung. Look, I own a strong core position and have paid for it by "trading" this for a few months now. I believe in what they are doing but also want to make money. No matter how much I buy and sell, it won't affect the s/p in any meaningful sense. But I'm going to take my $3-500 and more profits each time every chance I get with this or any other stock that allows me to. This bouncing from from the $2.70's to the $3-teen's range over and over is a dream come true for traders and investors alike. All one has to do is sit, watch and pounce. Doesn't mean I don't believe in the company.

When the real good news hits, I will have my shares, and I will see my portfolio value skyrocket. If the news never comes, I still will have made several thousand trading it.

Whether trading technicals, news or board action, there's plenty of profit to be made here. And it will continue unless no news comes for a sustained period or bad news arrives, which will both be the trading curtain call from CYDY in the Covid space.

Not fishy at all. Simple supply vs demand equation. The sizzle has been sold and the steak hasn't. .07 to .36 the past month or so ain't too shabby, but was all Covid related. Those buyers are gone now and with the world getting back to normal somewhat, and new treatments getting hyped, the allure of this stock unfortunately has waned. That doesn't mean this can't giddyap over the coming weeks, but it needs to give potential buyers some new positive news, data, etc. on something, anything in their pipeline.

New buyers aren't going to come from the March/April news merits, and current holders won't be pouring in new money with the status quo from the company.

Agree. The answer lies in the treatment(s), not the vaccine.

If given late at hospitalization, Leronlimab looks like a top choice among many other mid-late stage drugs like Remd and Tocil, or at least has a good enough or better profile to compete very well.

That said, my choice at the hospitalization stage would be convalescent plasma first, if available.

This will all end once a bona fide, non politicized treatment at home BEFORE needing hospitalization is shared worldwide. Right now, it "appears" that HCQ+Azith+Zinc is the front runner if given early and prior to hospitalization.

People will unfortunately still die from this regardless of a treatment or vaccine. Just like every other virus in the world.

NAH, there are no Covid therapies, honestly, any more real or proven than Leronlimab at this point. All players have a shot at pay dirt. It will depend on the ammo and the shooter, and if the mab shows success in the trials, which it should, we will have the marksman needed to hit the bullseye. No way he can screw it up.

Cytodyn back to $3.50 w/in a month imo.

This one? https://www.hotel-online.com/press_releases/release/las-vegas-executive-to-take-over-caesars-properties-in-atlantic-city

I just found this board, and I have to say, that after being on Ihub for almost 15 years, I have never ever ever seen anything like this company and board. Without question one of the most disturbing (in an oddly fun way) boards here. Are these 8K's supposed to be a joke? Is this CFO poster a joke? Are we all getting punked? How is this symbol actually trading?? How are they not shut down yet?? Trying to wrap my head around this complete lunacy! But man! It sure is entertaining to read.

Will this trial work? Lest we forget:

GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.

In other words...calms the cytokine storm. Trial has good history with it so we shall see.

https://ashpublications.org/blood/article/133/7/697/260575/GM-CSF-inhibition-reduces-cytokine-release

20 years old. Unreal. Well hey, here's a 1955 article with good info on nucleic acid content. But no mention, curiously, of Patterson or NP. Oh well, both articles are equals in their non relevancy to CYDY.

https://www.nature.com/articles/175209a0

Laughing?? Curious as to why anyone would be laughing. Remdesivir is made by Gilead, a $105 BILLION dollar company with a stock price of $83.00 and ties to every political hack in the world. Of COURSE it would be all over the news by the Fauci comments.

Leronlimab made by a company that's virtually unknown but trying hard, and on the brink of something special, trading at $3.20

Laughing because of a CC scheduled? Hmmm...nah, I don't think many people are laughing or again, can fathom why anyone would be.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=155105567

Just 12 days ago????

Correct...can't help but think he was referencing Tocilizumab in his statement. That drug really gaining momentum in the Covidsphere. Eh, but I don't know any more than the next guy. All I know is that if management does their job right and results are documented and reviewed in a positive manner, this $3's s/p will be long gone history.

A Cedars-Sinai research team is in the pre-clinical stages of developing a technology that harnesses intermittent ultraviolet (UV) A light for treating viruses and bacteria. The technology has not been tested or used on patients. Cedars-Sinai has filed for patents related to the technology and has signed a licensing agreement with Aytu BioScience with the aim of potentially enabling near-term use as a COVID-19 intervention for critically ill, intubated patients.

https://www.cedars-sinai.org/newsroom/cedars-sinai-statement-on-uv-a--technology/

Humanised monoclonal antibody drug leronlimab has shown ‘impressive results’ in a small observational Covid-19 study, said the drug’s developer CytoDyn CEO Dr Nader Pourhassan in a conference call.

Originally developed to treat HIV, the drug is a CCR5 antagonist that inhibits viral entry. It is undergoing Phase II clinical trials as a treatment for HIV and secured fast-track designation from the US Food and Drug Administration (FDA).

The drug’s ability to mitigate cytokine storm is the basis for its study as a potential Covid-19 treatment.

The Covid-19 trial of the drug enrolled ten patients under emergency new drug authorisations at Montefiore Medical Center at the Albert Einstein College of Medicine, New York City, US.

According to initial data, leronlimab reduced the plasma viral load and restored the immune system of Covid-19 patients.

Diagnostic firm IncellDX CEO Dr Bruce Patterson also noted that the drug decreased plasma viral load and restored immune cells. IncellDX’s lab analysed blood samples of the first ten patients in the Covid-19 trial.

Patterson said: “That is remarkable for one drug to restore the immune system and decrease the viral burden in these patients. That is what gives us great hope and great excitement about leronlimab going forward in these trials.”

https://www.clinicaltrialsarena.com/news/cytodyn-leronlimab-covid-19-data/

Not a problem at all imo. Those guys have done this before with derivative suits. Shares could be rescinded or there could be a settlement for some of the shares, or the court will rule against the plaintiffs.

Nah, not LOL....Meh, it's Seeking Alpha. Nothing to see here...

Well then THANK YOU to them!!! Brilliant as all heck as the s/p up from .30 to reaching 3.80's in 4 mos woohoo! Thanks for the pic it's terrific!

Nah, just smart marketing compared to others with a higher highs trend = NO P&D.

Nah, as I stated...it doesn't matter. It can be spun any way one likes, but them not buying on the open market is a 1000% non issue. End of story. And $1.34 to $3.55 in 4 mos and holding is HARDLY a P&D. So the money they spent on promotion seems to be WORKING.

Nah, who cares...we don't sweat or care over the littlest of things like that.

But here you go: 360-980-8524

Nah, to shareholders who know what they have, that's just not important. At all. The majority of legit CEO's rarely buy stock with cash on the open market. It would be a positive if he did as a confidence boost, but the fact that he hasn't in no way shape or form signals a negative.

Nah, won't ever have to give up. Famotidine is just one of 1,000 things they are throwing at this virus, like Vit D and C for example. Has ZERO to do with Leronlimab's potential and process.

Nah, not an advertisement in any sense of the word. James Rogers is a well known FOX reporter. No disclaimers or forward looking statements...straight up legit piece.

Nah, people who know, know that they went from the B team to the A team to help with these glorious times ahead. And this was in the works for a while now.

Mulholland is the guy we want. Trust that fact. Their resumes are exponentially worlds apart. We needed to bring in the big gun for what lies ahead for CYDY.

VERY positive sign indeed.

Yeah that was a typo...thanks.

I'm not in the field but let's keep it simple. The goal is to basically weaken the huge immune response in the body when trying to fight off C-19. Leronlimab does just that by lowering the inflammatory protein IL-6 in the body...remember, this is an HIV med targeting the RANTES receptor, CCR5, which blocks viral entry.Also remember, this is being re-purposed, and from the start, similarities between C-19 and HIV was seen by scientists worldwide. Tolcilizumab by Roche pretty much the same idea.

This stock will either go to $10-15 easy or stay at where it is. If management can follow through, and results are postive, I'm betting on former. I've spoken to a few of these people, and I don't get the sense at all that it's hype per se. Excitement? Absolutely. Hype? eh, not getting that vibe. And I didn't today on the CC either.

Nah, they are one in the same. Click on Qualcomm on the landing page. It'll take you to the same platform as CYDY's conference call.

Nah, it's Incomm's platform. Just open it up and CLICK ON ANY OF THE COMPANIES AND YOU WILL SEE IT AT THE SAME 78449.themediaframe.com prefix as CYDY's.

Cheeseandrice seriously??? ..HERE'S YOUR DD!!!!!!!

https://www.incommconferencing.com/mediaframe